Abstract:Genomic variations influencing response to pharmacotherapy of pain are currently under investigation. Drug-metabolizing enzymes represent a major target of ongoing research in order to identify associations between an individual's drug response and genetic profile. Polymorphisms of the cytochrome P450 enzymes (CYP2D6) influence metabolism of codeine, tramadol, hydrocodone, oxycodone and tricyclic antidepressants. Blood concentrations of some NSAIDs depend on CYP2C9 and/or CYP2C8 activity. Genomic variants of t… Show more
“…In addition, the threshold of experimental pain by codeine is increased in CYP2D6 EMs but not in PMs, who lack the activation machinery. However, evidence for impaired analgesic outcome in CYP2D6 PMs is sparse, and it has been postulated that large-scale studies will be needed to demonstrate genetically determined unresponsiveness to codeine analgesia (Smith, 2009;Stamer et al, 2010).…”
Section: B Prodrug Bioactivation By Cytochrome P450 Enzymesmentioning
confidence: 99%
“…In one study, the proportion of tramadol nonresponders was increased in the CYP2D6 PM group compared with the patients with functionally active CYP2D6 alleles. Thus, there is evidence that CYP2D6 polymorphisms can influence the efficacy of codeine and tramadol analgesia, although in most trials, only a limited number of patients have been monitored (Stamer et al, 2010).…”
Section: B Prodrug Bioactivation By Cytochrome P450 Enzymesmentioning
“…In addition, the threshold of experimental pain by codeine is increased in CYP2D6 EMs but not in PMs, who lack the activation machinery. However, evidence for impaired analgesic outcome in CYP2D6 PMs is sparse, and it has been postulated that large-scale studies will be needed to demonstrate genetically determined unresponsiveness to codeine analgesia (Smith, 2009;Stamer et al, 2010).…”
Section: B Prodrug Bioactivation By Cytochrome P450 Enzymesmentioning
confidence: 99%
“…In one study, the proportion of tramadol nonresponders was increased in the CYP2D6 PM group compared with the patients with functionally active CYP2D6 alleles. Thus, there is evidence that CYP2D6 polymorphisms can influence the efficacy of codeine and tramadol analgesia, although in most trials, only a limited number of patients have been monitored (Stamer et al, 2010).…”
Section: B Prodrug Bioactivation By Cytochrome P450 Enzymesmentioning
“…Current guidelines on translating pharmacogenomics into clinical practice seem to bring some promise (3). It is important, however, to bear in mind that pharmacogenetics/pharmacogenomics is just a tool that has to be assessed with other relevant factors that may affect drug behaviour, including age, gender, comorbidities, and other concomitant drugs (63). This approach will improve treatment with NSAIDs while avoiding serious adverse effects.…”
Interindividual variability in drug metabolism is an important cause of adverse drug reactions and variability in drug efficiency. Polymorphisms of cytochrome P450 (CYPs) genes have a significant effect on drug metabolism and toxicity. This review brings an update about how genetic polymorphisms of CYP2C8 and CYP2C9 enzymes affect the disposition and clinical outcomes of ibuprofen and diclofenac, two of the most common pain relievers. The most common side effects associated with the influence of CYP2C8*3 and CYP2C9*2*3 variants on ibuprofen and diclofenac pharmacokinetics are hepatotoxicity and gastrointestinal bleeding. CYP genotyping may therefore identify patients at increased risk of these adverse reactions, and these patients could have their doses adjusted or start receiving another NSAID that does not share the same metabolic pathways with ibuprofen or diclofenac. However, before genotyping is introduced into regular clinical practice, more research is needed to evaluate the effectiveness of this strategy in improving treatment with ibuprofen and diclofenac.
“…64 In addition, many agents comprising mainstream pharmacotherapy would benefit marginally from widespread pharmacogenetics testing because of the cost of the agents. However, certain NSAIDs (foe example, lumiracoxib) may have been able to positively affect patient care with the use of prospective genomic testing to aid in the identification of patients who had a variation in the HLA-DQA1*0102 allele, 32 preventing hepatic impairment and possible hepatotoxicity.…”
With the beginning of the Human Genome Project, an emerging field of science was brought to the forefront of the pharmaceutical community. Pharmacogenetics facilitates optimization of the current patient-centered care model and pharmacotherapy as a whole. Utilizing these ever-expanding branches of science to nonsteroidal anti-inflammatory drugs (NSAIDs) can provide novel opportunities to affect patient care. With a wide range of NSAID choices available as treatment options for relieving pain and/or reducing inflammation or fever, a more systematic way of selecting the ideal agent for the patients based upon their genetic information could spare them from a potentially permanent health-care condition. Furthermore, if a patient possesses or lacks certain alleles, serious adverse events can be anticipated and avoided. The tailoring of drug therapy can be achieved using the published data and cutting-edge genetic testing to attain a higher standard of care for patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.